PE-22-28 and Selank Interaction: Synergistic | Peptide Database

The original 2017 mouse study used 5 mg/kg IP, 3 times on alternate days. For a 60kg human, this translates to approximately 25mg per dose, administered as 3 doses every other day (75-100mg total per cycle). However, human pharmacokinetics differ significantly from mice, making these translations speculative.

Used off-label at 0.5mg daily for male pattern hair loss. Clinical trials demonstrate superior efficacy compared to finasteride, with greater increases in target area hair count attributed to dual 5-alpha reductase inhibition and more complete DHT suppression. Strong evidence for regrowth at the vertex region, where DHT-sensitive follicles are most concentrated. The greater DHT suppression achieved by dutasteride may provide additional benefit over finasteride in this area. Effective at slowing frontal hairline recession and improving mid-scalp density. Some evidence suggests dutasteride's dual inhibition provides a modest advantage over finasteride for frontal hair loss, though results vary between individuals. Some men who do not respond adequately to finasteride may benefit from switching to dutasteride, as the additional Type I inhibition provides more complete DHT suppression. Not all finasteride non-responders will respond to dutasteride. FDA-approved at 0.5mg daily for the treatment of symptomatic BPH. Reduces prostate volume by approximately 25% and improves urinary symptoms and flow rate over 6-12 months of treatment. Consistently reduces prostate volume more effectively than finasteride due to dual isoform inhibition, with reductions of 25-30% documented in long-term clinical trials.